What are the current NCCN treatment guidelines for squamous‑cell non‑small‑cell lung cancer across stages I to IV?

Treatment Guidelines for Squamous Cell Lung Cancer

For metastatic squamous cell lung cancer, first-line treatment depends on PD-L1 expression: pembrolizumab monotherapy for PD-L1 ≥50%, or pembrolizumab/carboplatin/paclitaxel (or nab-paclitaxel) combination for PD-L1 <50% or unknown, with immunotherapy-based regimens now preferred over chemotherapy alone for eligible patients. 1

Stage-Specific Treatment Approach

Early Stage Disease (Stages I-III)

• Stages I-II: Surgical resection remains the primary treatment for resectable disease, with consideration of neoadjuvant or adjuvant systemic therapy for eligible patients 2, 3
• Stage III: Multimodality treatment incorporating surgery, radiation, and systemic therapy based on resectability 1

Metastatic Disease (Stage IV)

First-Line Therapy Selection Algorithm

Step 1: Assess Performance Status and PD-L1 Expression

For PS 0-1 patients:

• PD-L1 ≥50%: Pembrolizumab monotherapy is the preferred option 1
• PD-L1 <50% or unknown: Pembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel) is recommended as the standard first-line regimen 1
• Alternative for PD-L1 <50%: Atezolizumab plus carboplatin and nab-paclitaxel represents another option 1
• High tumor mutational burden (TMB): Nivolumab plus ipilimumab is an option regardless of PD-L1 expression if TMB can be accurately evaluated 1

For PS 2 patients:

• Combination chemotherapy or single-agent chemotherapy may be considered after thorough discussion of risks and benefits 1
• Platinum-based doublets can be offered to selected PS 2 patients who desire aggressive treatment 1

For PS 3-4 patients:

• Best supportive care is recommended 1

Chemotherapy Regimens (when immunotherapy contraindicated)

Platinum-based doublets are the backbone:

• Carboplatin-based combinations (preferred for squamous histology):

  • Carboplatin plus paclitaxel 1
  • Carboplatin plus nab-paclitaxel 1

• Cisplatin-based combinations:

  • Cisplatin plus paclitaxel 1
  • Cisplatin plus docetaxel 1
  • Cisplatin plus vinorelbine 1

• Duration: Four cycles of platinum-based chemotherapy are recommended, with a maximum of six cycles 1

Important caveat: Pemetrexed should NOT be used in squamous cell carcinoma—it is restricted to non-squamous histology 1

Second-Line Therapy Options

For PS 0-2 patients with disease progression:

Preferred immunotherapy options:

• Nivolumab (highest level of evidence) 1, 4
• Atezolizumab 1
• Pembrolizumab if PD-L1 >1% 1

Chemotherapy options:

• Docetaxel 1
• Ramucirumab plus docetaxel 1

Targeted therapy:

• Erlotinib (lower level of evidence) 1
• Afatinib 1

Third-Line and Beyond

• Erlotinib or gefitinib if not previously received 1
• Insufficient data to recommend routine third-line cytotoxic chemotherapy 1

Critical Testing Considerations

Molecular testing is generally NOT recommended in squamous cell carcinoma, except in rare circumstances when found in never-smokers, long-time ex-smokers, or light smokers (<15 pack-years) 1

However, if testing is performed and actionable mutations are identified (EGFR, ALK, ROS1, BRAF V600E, RET, MET), targeted therapy should be prioritized according to mutation-specific guidelines 1, 5

Essential Supportive Care

Early palliative care integration is mandatory: Concomitant palliative care from diagnosis has been shown to improve both survival and quality of life in stage IV NSCLC and should be initiated immediately 1

Common Pitfalls to Avoid

• Do not use pemetrexed in squamous cell carcinoma—this is a critical error that reduces efficacy 1
• Do not skip PD-L1 testing before selecting first-line therapy, as it directly impacts treatment selection 1
• Do not withhold treatment based on age alone—treatment decisions should be based on performance status and comorbidities 1
• Do not continue platinum beyond 4-6 cycles unless part of a maintenance strategy 1